Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bausch & Lomb

This article was originally published in The Tan Sheet

Executive Summary

U.S. Patent & Trademark Office grants Bausch & Lomb's patent for Ocuvite PreserVision antioxidant mineral formula Dec. 9. The same day, the Rochester, N.Y.-based company filed lawsuits in U.S. District Court against Alcon Labs, GNC, Leiner and Rexall Sundown, alleging that their respective eye vitamin products infringe on its patent rights. A study in the Archives of Ophthalmology November issue found that if, over the next five years, all those at risk of developing age-related macular degeneration took Ocuvite PreserVision, more than 300,000 people would avoid advanced ADM and any associated vision loss (1"The Tan Sheet" Nov. 17, 2003, p. 11). At a recent Bear Stearns conference, B&L CFO Steve McCloskey predicted the Ocuvite brand, which had around $50 mil. in sales in 2002, could reach $100 mil. to $200 mil. in the next few years (2"The Tan Sheet" Sept. 15, 2003, p. 6)...

You may also be interested in...

Eye Supplement Use Could Have “Major” Public Health Impact, Study Says

If all those at risk for developing age-related macular degeneration received dietary supplements like Bausch & Lomb's Ocuvite PreserVision, more than 300,000 of them would avoid advanced AMD and any associated vision loss during the next five years, according to a study in the November Archives of Ophthalmology.

Bausch & Lomb To Spur Lens Care Sales With New Solution Launch

Bausch & Lomb plans to boost top line growth in its lens care category with the introduction of a new "first of its kind" lens solution next year

Could SillaJen Get Back On Track Via M2N Acquisition?

SillaJen selects another Korean firm as its new owner as trading in its stock continues to be suspended following the probe into its former CEO. But it remains to be seen whether the acquisition can catalyze a business breakthrough and speed up clinical development for the oncolytic immunotherapeutic firm.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts